Command Palette

Search for a command to run...

INDGN
550(-1.19%)
1W: -0.78%

Indegene Peer Comparison

Snapshot Summary

Indegene Ltd. stands out in the Pharmaceuticals & Drugs sector with impressive revenue growth and profitability metrics compared to its peers. Despite a high PE ratio, its strong ROE and significant revenue growth signal healthy operational performance, making it a potential growth stock. However, caution is advised due to a relatively high PEG ratio, suggesting that growth may be priced in.

  • Indegene Ltd. shows a robust revenue growth of 9.64% YoY and a notable 38.9% over three years.
  • High ROE of 27.56%, indicating effective management and profitability.
  • Despite a high PE ratio of 72.37, the growth prospects remain attractive.
  • Mankind Pharma Ltd.: Highest revenue growth over three years at 155.25% and strong cash flow metrics.
  • Dr. Reddy's Laboratories Ltd.: Best profitability with a PE of 15.50 and strong EPS growth, making it a value pick.
Stocks
CMP
Market Cap
P/E
ROCE (%)
Debt/Equity
INDGN₹546.55₹13,121.01Cr72.3730.88%0.29
SUNPHARMA₹1,563.35₹3,75,099.26Cr87.5917.60%0.04
DIVISLAB₹6,091.05₹1,61,698.50Cr73.2016.46%-
CIPLA₹1,587.60₹1,28,217.27Cr23.7322.77%0.01
TORNTPHARM₹3,581.55₹1,21,215.77Cr61.5324.28%0.57
DRREDDY₹1,280.30₹1,06,835.27Cr15.5026.86%0.07
MANKIND₹2,518.95₹1,03,926.59Cr55.1828.38%0.02

Leveling the playing field in markets.

© 2025 EQHQ Technologies Pvt Ltd

"Information provided is for educational purposes only and not financial advice.